Warts and All: Verrica and Torii Team Up to Fund Global Phase 3 Trial of YCANTH for Common Warts
Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii) to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH (cantharidin) for the treatment of common warts. With a prevalence of approximately 22 million patients in the U.S. alone and no FDA approved therapies, common […]